NXTS vs AMGN vs GILD Stock Comparison

Nexentis Technologies, Amgen and Gilead Sciences Prices as of Nov 13, 2026 Peers: Industry group
AMGN Amgen Inc
$465.67 +9.3% 1M +38.6% 1Y
Market cap
$250.76B
P/E
26.7x
Revenue (TTM)
$38.90B
Div. yield
0.02%
Biotechnology Healthcare
6 wins
GILD Gilead Sciences, Inc.
$168.08 +9.5% 1M +34.2% 1Y
Market cap
$208.18B
P/E
–
Revenue (TTM)
$30.99B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

9 decided of 12

Amgen leads on 6 of the 12 questions below (Amgen 6, Gilead Sciences 2, Nexentis Technologies 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNXTSAMGNGILDLeader
Larger companyMarket capitalisation $330.53K $250.76B $208.18B AMGN
Cheaper on earningsLower P/E, profitable companies only 0.0x 26.7x -53.9x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 20.9x — –
Faster revenue growthRevenue growth, trailing twelve months -4,237.5% +8.2% +6.5% AMGN
More profitableNet margin, trailing twelve months — 24.1% -12.5% AMGN
Better return on capitalReturn on invested capital — 15.6% -6.1% AMGN
Less leveragedLower net debt / EBITDA 0.8x 2.4x 43.8x NXTS
Higher dividend yieldTrailing dividend yield 0.00% 0.02% 0.00% –
Better 1-year returnPrice return, last 12 months -90.3% +38.6% +34.2% AMGN
Better 5-year returnAnnualised price return, 5 years -82.4%/yr +17.1%/yr +20.0%/yr GILD
Less volatileAnnualised volatility, 1 year 235.4% 28.8% 27.5% GILD
Higher overall scoreMean of the five percentile scores vs peers 18/100 66/100 61/100 AMGN

Percentile Scorecard

NXTSAMGNGILD

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNXTSAMGNGILD
Valuation 7 #612 of 660 85 #103 of 660 89 #71 of 660
Growth 6 #585 of 619 61 #245 of 619 34 #408 of 619
Profitability 22 #462 of 595 95 #32 of 595 85 #91 of 595
Financial Health 38 #423 of 683 23 #528 of 683 22 #530 of 683
Shareholder Returns – 67 #152 of 459 75 #116 of 459
Overall 18 66 61
  • NXTS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • AMGN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • GILD ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNXTSAMGNGILDSPY
1 month +229.2%+9.3%+9.5% -2.0%
3 months +12.0%+12.2%+21.5% -2.8%
6 months -52.0%+42.7%+29.7% +2.0%
Year to date -81.8%+42.3%+36.9% +10.6%
1 year -90.3%+38.6%+34.2% +12.2%
3 years -99.6%+72.5%+124.9% +68.1%
3 years, per year -84.2%+19.9%+31.1% +18.9%
5 years -100.0%+120.3%+149.1% +61.4%
5 years, per year -82.4%+17.1%+20.0% +10.1%
10 years -100.0%+212.4%+119.9% +248.5%
10 years, per year -61.8%+12.1%+8.2% +13.3%

Risk

MeasureNXTSAMGNGILDSPY
Volatility, 1Y 235.4%28.8%27.5% 13.6%
Downside volatility, 1Y 158.4%28.4%24.0% 13.9%
Beta vs S&P 500, 1Y 4.330.490.39 1.00
Return / volatility, 1Y -0.381.341.25 0.90
Max drawdown, 5Y -100.0%-26.7%-29.4% -25.4%
From 52-week high -90.5%-2.7%-3.7% -3.2%
52-week high $22.54$478.48$174.48 $779.14
52-week low $0.48$313.85$118.30 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNXTSAMGNGILD
P/E now vs peer median 0.0xmedian 17.0x 26.8xmedian 17.0x -54.0xmedian 17.0x
P/S now vs peer median 0.0xmedian 8.4x 6.5xmedian 8.4x 6.7xmedian 8.4x
EV/EBITDA now vs peer median 0.8xmedian 14.6x 17.1xmedian 14.6x 505.3xmedian 14.6x
P/FCF now vs peer median -0.1xmedian 19.0x 26.3xmedian 19.0x 15.1xmedian 19.0x
P/B now vs peer median 0.2xmedian 2.0x 17.6xmedian 2.0x 16.0xmedian 2.0x
PEG now vs peer median 0.00median 0.43 3.86median 0.43 1.40median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNXTSAMGNGILD
Revenue -$8.94M $38.90B $30.99B
Gross profit – $27.58B $24.77B
Operating income -$10.88M $12.61B -$2.36B
Net income -$16.14M $9.39B -$3.86B
Free cash flow -$4.50M $9.58B $13.78B
R&D $798.00K $7.84B $6.33B
EPS (diluted) $-98.21 $17.20 $-3.09
Cash & equivalents $7.62M $13.19B $6.44B
Total debt $422.00K $54.01B $26.23B
Shares (diluted) 163.23K 546.00M 1.25B
Enterprise value -$25.11M $202.42B $183.29B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNXTSAMGNGILD
P/E 0.0x 26.8x -54.0x
P/FCF -0.1x 26.3x 15.1x
P/Operating cash flow -0.1x 20.9x 14.4x
P/S 0.0x 6.5x 6.7x
P/B 0.2x 17.6x 16.0x
P/Tangible book -0.2x -48.6x -543.2x
EV/EBITDA 0.8x 17.1x 505.3x
EV/EBIT 0.7x 23.2x -96.7x
EV/Revenue 0.9x 7.5x 7.4x
EV/FCF 1.8x 30.5x 16.6x
EV/Operating cash flow 1.8x 24.3x 15.8x
PEG (3Y EPS CAGR) 0.00 3.86 1.40

Growth

14 metrics
MetricNXTSAMGNGILD
Revenue growth (1Y) -4,238% 8.2% 6.5%
Revenue CAGR (3Y) -182.9% 13.2% 4.2%
Gross profit growth (1Y) – 15.9% 8.2%
Gross profit CAGR (3Y) – 11.8% 4.7%
Operating income growth (1Y) -127.3% 45.4% -122.5%
Operating income CAGR (3Y) -23.5% 12.5% -31.7%
Net income growth (1Y) -70.1% 34.1% -147.6%
Net income CAGR (3Y) -42.2% 7.5% -38.5%
EPS growth (1Y) -666.2% 33.1% -147.7%
EPS CAGR (3Y) -52.0% 6.9% -38.6%
Operating cash flow growth (1Y) -62.8% -8.3% 49.8%
Operating cash flow CAGR (3Y) -0.4% 4.4% 19.9%
Free cash flow growth (1Y) -65.5% -17.0% 50.4%
Free cash flow CAGR (3Y) -0.7% 0.7% 20.6%

Profitability

14 metrics
MetricNXTSAMGNGILD
Gross margin – 70.9% 79.9%
EBITDA margin – 43.9% 1.5%
Operating margin – 32.4% -7.6%
Pretax margin – 28.4% -8.2%
Net margin – 24.1% -12.5%
FCF margin – 24.6% 44.5%
Operating cash flow margin 49.6% 30.9% 46.7%
Return on equity -218.6% 72.1% -31.2%
Return on assets -92.0% 9.8% -7.7%
Return on invested capital – 15.6% -6.1%
Return on capital employed -73.7% 17.4% -6.2%
Asset turnover -0.5x 0.4x 0.6x
Cash conversion (OCF / net income) 0.3x 1.3x -3.7x
Stock comp / revenue -11.0% 1.3% 2.9%

Financial Health

11 metrics
MetricNXTSAMGNGILD
Debt / assets 2.3% 56.2% 51.0%
Debt / equity 0.2x 3.8x 2.0x
Net debt / EBITDA 0.8x 2.4x 43.8x
Debt / FCF -0.1x 5.6x 1.9x
Liabilities / assets 89.8% 85.1% 74.6%
Equity / assets 10.2% 14.9% 25.4%
Interest coverage – 4.8x -2.3x
Current ratio 3.7x 1.5x 1.4x
Quick ratio 3.2x 1.0x 1.0x
Cash ratio 3.2x 0.6x 0.5x
Altman Z-score -6.11 2.54 3.90

Shareholder Returns

7 metrics
MetricNXTSAMGNGILD
Dividend yield – 2.1% 1.9%
Net buyback yield -2,794% – 0.5%
Shareholder yield -2,794% 2.1% 2.5%
Payout ratio (earnings) – 57.1% –
Payout ratio (FCF) – 56.0% –
Dividend growth (1Y) – 6.3% –
Dividend CAGR (3Y) – 6.4% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNXTSAMGNGILD
Forward P/E – 20.9xFY2026 –
EPS, next fiscal year – $22.28FY2026 $-0.84FY2026
EPS growth, next FY – +2.0%FY2026 -110.3%FY2026
EPS growth, the year after – +7.2% –
Revenue, next fiscal year – $42.01BFY2026 $29.15BFY2026
Revenue growth, next FY – +14.3%FY2026 -1.0%FY2026
Revenue growth, the year after – +3.1% +18.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNXTSAMGNGILD
Held by institutions – 82.7% 89.6%
Institutions holding – 3,163 2,293
Change in shares held, QoQ – +4.5% +5.1%
Institutions buying – 1,452 1,113
Institutions selling – 1,219 853
Buyers to sellers – 1.19 1.30

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NXTSAMGNGILD
NXTS 1.00 0.04 0.06
AMGN 0.04 1.00 0.57
GILD 0.06 0.57 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NXTS, AMGN and GILD?

Amgen (AMGN) is the largest by market capitalisation: Nexentis Technologies (NXTS) $330.53K, Amgen (AMGN) $250.76B, Gilead Sciences (GILD) $208.18B.

Which company is growing faster?

Amgen (AMGN) grew revenue fastest over the trailing twelve months: Nexentis Technologies (NXTS) -4,237.5%, Amgen (AMGN) +8.2%, Gilead Sciences (GILD) +6.5%.

Which company is more profitable?

Amgen (AMGN) has the highest net margin (Amgen (AMGN) 24.1%, Gilead Sciences (GILD) -12.5%). On return on invested capital, Amgen (AMGN) leads (Amgen (AMGN) 15.6%, Gilead Sciences (GILD) -6.1%).

Which stock has performed better?

Over the past year Amgen (AMGN) returned the most: Nexentis Technologies (NXTS) -90.3%, Amgen (AMGN) +38.6%, Gilead Sciences (GILD) +34.2%. Over five years, Gilead Sciences (GILD) compounded fastest (Nexentis Technologies (NXTS) -82.4%/yr, Amgen (AMGN) +17.1%/yr, Gilead Sciences (GILD) +20.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Nexentis Technologies (NXTS) 0.00%, Amgen (AMGN) 0.02%, Gilead Sciences (GILD) 0.00%. Nexentis Technologies (NXTS) and Gilead Sciences (GILD) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Gilead Sciences (GILD) has been the steadiest (Nexentis Technologies (NXTS) 235.4%, Amgen (AMGN) 28.8%, Gilead Sciences (GILD) 27.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NXTS, AMGN and GILD?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amgen (AMGN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.